Skip to content

Assessment of the Impact of Polycystic Ovary Syndrome on Women's Sexuality

Assessment of the Impact of Polycystic Ovary Syndrome on Women's Sexuality

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06887296
Acronym
SexOPK
Enrollment
84
Registered
2025-03-20
Start date
2025-06-30
Completion date
2025-10-24
Last updated
2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovarian Syndrome (PCOS)

Keywords

Polycystic Ovary Syndrome, Female Sexuality, Quality of Life, Sexual Health

Brief summary

This study, titled SexOPK, aims to evaluate the impact of polycystic ovary syndrome (PCOS) on women's sexual health. PCOS is a common endocrine disorder affecting 5-20% of women of reproductive age, often leading to hormonal imbalances, metabolic issues, and psychological distress. Despite existing studies on the subject, the level of sexual distress associated with PCOS-related sexual dysfunction remains unclear. The study will compare sexual function and distress levels between women diagnosed with PCOS and a control group without PCOS. Participants will complete an online questionnaire assessing various aspects of sexual health, body image, anxiety, and depression. The findings may help healthcare professionals better understand and address sexual dysfunction in women with PCOS.

Interventions

OTHERwomen answer a questionnaire

Sexual Function and Distress Assessment in Women with Polycystic Ovary Syndrome (PCOS) Using Standardized Questionnaires

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

For patients in the test group (PCOS): * Adults * Carriers of medically diagnosed polycystic ovarian syndrome * Non-opposition For patients in the control group: * Adults * Not carriers of polycystic ovarian syndrome * Unopposed

Exclusion criteria

* Patient under court protection, guardianship, or curatorship * Does not understand or speak French

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of Sexual Function and Distress in Women with Polycystic Ovary Syndrome Using BISF-W ScoresDay 1The Brief Index of Sexual Functioning for Women (BISF-W) is a validated questionnaire that assesses various aspects of female sexual function, including desire, arousal, frequency of sexual activity, receptivity, orgasm, satisfaction, and concerns affecting sexuality. It consists of 22 items, generating a composite score that reflects overall sexual well-being. Higher BISF-W scores indicate better sexual function, while lower scores suggest sexual dysfunction or distress.
Evaluation of Sexual Function and Distress in Women with Polycystic Ovary Syndrome Using FSDS-R ScoresDay 1The Female Sexual Distress Scale-Revised (FSDS-R) is a 13-item questionnaire designed to measure sexual distress in women, including feelings of frustration, guilt, stress, and dissatisfaction related to sexual activity. The total score ranges from 0 to 52, with higher scores indicating greater sexual distress and lower scores reflecting better emotional well-being regarding sexuality

Secondary

MeasureTime frameDescription
Assessment of Body Image Satisfaction Using the QIC QuestionnaireDay 1The third part corresponds to the QIC questionnaire (Body Image Questionnaire), which includes 19 items and explores body satisfaction/dissatisfaction indirectly, by taking into account a set of desirable/undesirable bodily attributes and states
Evaluation of Anxiety and Depression Using the HADS ScaleDay 1The Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire designed to assess anxiety and depression symptoms in non-psychiatric medical settings. It consists of two subscales: HADS-A (7 items for anxiety) and HADS-D (7 items for depression). Each item is scored from 0 to 3, leading to subscale scores ranging from 0 to 21 and a total score from 0 to 42. For each subscale, a lower score (0-7) indicates normal emotional status, 8-10 suggests a borderline case, and 11-21 reflects clinically significant anxiety or depression. A higher total score indicates greater psychological distress, while a lower score reflects better mental well-being.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORAnna Gosset

University Hospital of Toulouse

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026